Hangzhou Diagens Biotechnology Co Ltd (HKSE:02526) Share Price

Company Profile

Business description
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
Contact
No. 609 Hongfeng Road
Room 101, Building 1
Donghu Sub-district
Linping District, Zhejiang
Hangzhou
CHN
T: +86 4000680888
https://www.diagens.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
182

Recommended

International expansion is a distraction from valuable local business.

Roy Van Keulen | 14 May 2026

The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.

Jacob Robbins | 14 May 2026

How the most traded shares in April stack up against our analysts views.

Tyger Fitzpatrick | 14 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,870.60	46.70	-0.52%
CAC 40	7,952.55	129.72	-1.61%
DAX 40	23,950.57	505.69	-2.07%
Dow JONES (US)	49,526.17	537.29	-1.07%
FTSE 100	10,195.37	177.56	-1.71%
HKSE	25,962.73	426.31	-1.62%
NASDAQ	26,225.14	410.08	-1.54%
Nikkei 225	61,409.29	1,244.76	-1.99%
NZX 50 Index	12,965.01	60.06	-0.46%
S&P 500	7,408.50	92.74	-1.24%
S&P/ASX 200	8,630.80	42.70	-0.49%
SSE Composite Index	4,135.39	42.53	-1.02%